What does Tilt Biotherapeutics do?
Tilt Biotherapeutics is a Helsinki-based clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies. The company leverages a proprietary platform utilizing oncolytic adenoviruses armed with cytokines to activate T cells, destroy cancer cells, and modify the tumor microenvironment.
How much did they raise?
The company raised USD25M in Series B funding, led by the European Innovation Council Fund, Lifeline Ventures, Finnish Industry Investment, and Stephen Industries Inc Oy.
What are their plans for the money?
The funds will support a Phase 2 clinical trial of its lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, as well as Phase 1b trials in melanoma and other cancers. This investment is expected to accelerate the development of its immunotherapy portfolio and potentially transform treatment paradigms for hard-to-treat cancers.
What have they achieved so far?
Tilt Biotherapeutics has already secured over EUR72M to date and made significant advancements in its clinical development programs, including progress with its lead product, TILT-123.
